Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis

Annalisa Guida; Cristina Masini; Michele Milella; Giuseppe Di Lorenzo; Matteo Santoni; Veronica Prati; Camillo Porta; Laura Cosmai; Donatella Donati; Cinzia Del Giovane; Pasquale Mighali; Roberto Sabbatini

doi:10.2217/fon.15.256

Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis

Annalisa Guida, Cristina Masini, Michele Milella, Giuseppe Di Lorenzo, Matteo Santoni, Veronica Prati, Camillo Porta, Laura Cosmai, Donatella Donati, Cinzia Del Giovane, Pasquale Mighali, Roberto Sabbatini

Research output: Contribution to journal › Article › peer-review

Abstract

Aims: This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis. Patients & methods: From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected. Results: Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported. Conclusion: Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.

Original language	English
Pages (from-to)	3159-3166
Number of pages	8
Journal	Future Oncology
Volume	11
Issue number	23
DOIs	https://doi.org/10.2217/fon.15.256
Publication status	Published - 2015

Keywords

dialysis
everolimus
metastatic renal cell carcinoma

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon.15.256

Cite this

@article{21eb4e06df794a1db2e7e337870bb2bf,

title = "Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis",

abstract = "Aims: This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis. Patients & methods: From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected. Results: Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported. Conclusion: Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.",

keywords = "dialysis, everolimus, metastatic renal cell carcinoma",

author = "Annalisa Guida and Cristina Masini and Michele Milella and {Di Lorenzo}, Giuseppe and Matteo Santoni and Veronica Prati and Camillo Porta and Laura Cosmai and Donatella Donati and {Del Giovane}, Cinzia and Pasquale Mighali and Roberto Sabbatini",

year = "2015",

doi = "10.2217/fon.15.256",

language = "English",

volume = "11",

pages = "3159--3166",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "23",

}

TY - JOUR

T1 - Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis

AU - Guida, Annalisa

AU - Masini, Cristina

AU - Milella, Michele

AU - Di Lorenzo, Giuseppe

AU - Santoni, Matteo

AU - Prati, Veronica

AU - Porta, Camillo

AU - Cosmai, Laura

AU - Donati, Donatella

AU - Del Giovane, Cinzia

AU - Mighali, Pasquale

AU - Sabbatini, Roberto

PY - 2015

Y1 - 2015

N2 - Aims: This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis. Patients & methods: From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected. Results: Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported. Conclusion: Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.

AB - Aims: This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis. Patients & methods: From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected. Results: Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported. Conclusion: Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.

KW - dialysis

KW - everolimus

KW - metastatic renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84971619998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971619998&partnerID=8YFLogxK

U2 - 10.2217/fon.15.256

DO - 10.2217/fon.15.256

M3 - Article

C2 - 26544922

AN - SCOPUS:84971619998

SN - 1479-6694

VL - 11

SP - 3159

EP - 3166

JO - Future Oncology

JF - Future Oncology

IS - 23

ER -

Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this